The IPS results indicated that the COAD patients in the low-risk group were more likely to benefit from immunotherapy, regardless of whether it was administered without PD-1 and CTLA-4 inhibitors or with only CTLA-4 inhibitors, compared to the high-risk patients. This evidence concerns the gene PDCD1 and colon adenocarcinoma.